Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ABEONA THERAPEUTICS INC.ABEO · Entity 5808 | Director | September 26, 2022 | September 28, 2022 |
| ARYA Sciences Acquisition Corp VARYE · Entity 137308 | Director | July 12, 2021 | July 12, 2021 |
| ASP Isotopes Inc.ASPI · Entity 5371 | Director | June 29, 2026 | July 02, 2026 |
| Cerevel Therapeutics Holdings, Inc.ARYB · Entity 15182 | Director | June 04, 2020 | June 04, 2020 |
| Nautilus Biotechnology, Inc.ARYA · Entity 6679 | Director | August 06, 2020 | August 07, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ABEONA THERAPEUTICS INC.
Report date September 26, 2022 · Filed September 28, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 16,907 |
Reported balance
After 2022-09-26 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2022-09-26 · Grant · Acquired 13,400 · Balance 16,907 F1: All of the restricted stock will vest on September 26, 2023. F2: On July 1, 2022, the issuer effectuated a 1-for-25 reverse stock split. |
Filing footnotes · ownership attribution and instrument terms
F1: All of the restricted stock will vest on September 26, 2023.
F2: On July 1, 2022, the issuer effectuated a 1-for-25 reverse stock split.
ARYA Sciences Acquisition Corp V
Report date July 12, 2021 · Filed July 12, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class B ordinary sharesSEC Table II · derivative / convertible security | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2021-07-12 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance Not disclosed F1: As described in the issuer's registration statement on Form S-1 (File No. 333-257335) under the heading "Description of Securities--Founder Shares", the Class B ordinary shares, par value $0.0001 per share, will automatically convert into Class A ordinary shares, par value $0.0001 per share, of the issuer at the time of the issuer's initial business combination on a one-for-one basis, subject to adjustment for stock splits, stock dividends, reorganizations, recapitalizations and the like, and certain anti-dilution rights and have no expiration date. |
Filing footnotes · ownership attribution and instrument terms
F1: As described in the issuer's registration statement on Form S-1 (File No. 333-257335) under the heading "Description of Securities--Founder Shares", the Class B ordinary shares, par value $0.0001 per share, will automatically convert into Class A ordinary shares, par value $0.0001 per share, of the issuer at the time of the issuer's initial business combination on a one-for-one basis, subject to adjustment for stock splits, stock dividends, reorganizations, recapitalizations and the like, and certain anti-dilution rights and have no expiration date.
ASP Isotopes Inc.
Report date June 29, 2026 · Filed July 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 672,247 |
Ending reported balance
After 2026-06-30 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-06-29 · Sale · Disposed 50,000 · Balance 722,247 F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.21 to $6.31, inclusive. The reporting person undertakes to provide ASP Isotopes Inc. (the "Company"), any stockholder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Row 2 · 2026-06-30 · Sale · Disposed 50,000 · Balance 672,247 F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.10 to $6.25, inclusive. The reporting person undertakes to provide the Company, any stockholder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.21 to $6.31, inclusive. The reporting person undertakes to provide ASP Isotopes Inc. (the "Company"), any stockholder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.10 to $6.25, inclusive. The reporting person undertakes to provide the Company, any stockholder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
Cerevel Therapeutics Holdings, Inc.
Report date June 04, 2020 · Filed June 04, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class B ordinary sharesSEC Table II · derivative / convertible security | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2020-06-04 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance Not disclosed F1: As described in the issuer's registration statement on Form S-1 (File No. 333-238488) under the heading "Description of Securities--Founder Shares", the shares of Class B ordinary shares, par value $0.0001 per share, will automatically convert into shares of Class A ordinary shares, par value $0.0001 per share, of the issuer at the time of the issuer's initial business combination on a one-for-one basis, subject to adjustment for stock splits, stock dividends, reorganizations, recapitalizations and the like, and certain anti-dilution rights and have no expiration date. |
Filing footnotes · ownership attribution and instrument terms
F1: As described in the issuer's registration statement on Form S-1 (File No. 333-238488) under the heading "Description of Securities--Founder Shares", the shares of Class B ordinary shares, par value $0.0001 per share, will automatically convert into shares of Class A ordinary shares, par value $0.0001 per share, of the issuer at the time of the issuer's initial business combination on a one-for-one basis, subject to adjustment for stock splits, stock dividends, reorganizations, recapitalizations and the like, and certain anti-dilution rights and have no expiration date.
Nautilus Biotechnology, Inc.
Report date August 06, 2020 · Filed August 07, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class B ordinary sharesSEC Table II · derivative / convertible security | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2020-08-06 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance Not disclosed F1: As described in the issuer's registration statement on Form S-1 (File No. 333-239986) under the heading "Description of Securities--Founder Shares", the shares of Class B ordinary shares, par value $0.0001 per share, will automatically convert into shares of Class A ordinary shares, par value $0.0001 per share, of the issuer at the time of the issuer's initial business combination on a one-for-one basis, subject to adjustment for stock splits, stock dividends, reorganizations, recapitalizations and the like, and certain anti-dilution rights and have no expiration date. |
Filing footnotes · ownership attribution and instrument terms
F1: As described in the issuer's registration statement on Form S-1 (File No. 333-239986) under the heading "Description of Securities--Founder Shares", the shares of Class B ordinary shares, par value $0.0001 per share, will automatically convert into shares of Class A ordinary shares, par value $0.0001 per share, of the issuer at the time of the issuer's initial business combination on a one-for-one basis, subject to adjustment for stock splits, stock dividends, reorganizations, recapitalizations and the like, and certain anti-dilution rights and have no expiration date.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
ARYA SCIENCES ACQUISITION CORP.
Report date July 01, 2020 · Filed July 07, 2020
Section 16 reporting ended · disclosed 2020-07-07. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class B Ordinary SharesSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2020-07-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-07-01 · Disposition to issuer · Disposed 30,000 · Balance 0 F1: In connection with the merger of ARYA Sciences Acquisition Corp. (the "Issuer") with and into a subsidiary of Immatics N.V. ("IMTX"), and a series of related transactions (collectively, the "Business Combination"), the Class B Ordinary Shares, par value $0.0001 per share, of the Issuer held by the Reporting Person were exchanged for Ordinary Shares, nominal value EURO0.01 per share, of IMTX. Upon consummation of the Business Combination the Reporting Person is no longer subject to the reporting requirements of Section 16 with respect to the Issuer's securities. |
Filing footnotes · ownership attribution and instrument terms
F1: In connection with the merger of ARYA Sciences Acquisition Corp. (the "Issuer") with and into a subsidiary of Immatics N.V. ("IMTX"), and a series of related transactions (collectively, the "Business Combination"), the Class B Ordinary Shares, par value $0.0001 per share, of the Issuer held by the Reporting Person were exchanged for Ordinary Shares, nominal value EURO0.01 per share, of IMTX. Upon consummation of the Business Combination the Reporting Person is no longer subject to the reporting requirements of Section 16 with respect to the Issuer's securities.
ARYA Sciences Acquisition Corp IV
Report date July 31, 2024 · Filed August 01, 2024
Section 16 reporting ended · disclosed 2024-08-01. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class B ordinary sharesSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2024-07-31 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-07-31 · Disposition to issuer · Disposed 30,000 · Balance 0 F1: In connection with the Business Combination Agreement, dated February 13, 2024, by and among the Issuer, Adagio Medical Holdings, Inc. (f/k/a Aja HoldCo, Inc.) ("HoldCo"), Aja Merger Sub 1 ("Merger Sub 1"), Aja Merger Sub 2, Inc. ("Merger Sub 2") and Adagio Medical, Inc. ("Adagio") (the transactions contemplated thereby, the "Business Combination"), Merger Sub merged with and into the Issuer and Merger Sub 2 merged with and into Adagio, with each of the Issuer and Adagio becoming a wholly owned subsidiary of HoldCo, and the Reporting Person's ordinary shares of the Issuer were automatically converted into shares of common stock of HoldCo, par value $0.0001 per share, on a one-for-one basis. |
Filing footnotes · ownership attribution and instrument terms
F1: In connection with the Business Combination Agreement, dated February 13, 2024, by and among the Issuer, Adagio Medical Holdings, Inc. (f/k/a Aja HoldCo, Inc.) ("HoldCo"), Aja Merger Sub 1 ("Merger Sub 1"), Aja Merger Sub 2, Inc. ("Merger Sub 2") and Adagio Medical, Inc. ("Adagio") (the transactions contemplated thereby, the "Business Combination"), Merger Sub merged with and into the Issuer and Merger Sub 2 merged with and into Adagio, with each of the Issuer and Adagio becoming a wholly owned subsidiary of HoldCo, and the Reporting Person's ordinary shares of the Issuer were automatically converted into shares of common stock of HoldCo, par value $0.0001 per share, on a one-for-one basis.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 30, 2026 Filed Jul 2, 2026 01:45 UTC | ASP Isotopes Inc. ASPI · Entity 5371 | SaleCommon Stock | 50,000 | $6.12 | $306,000.00 |
DisclosureSEC source: 0001477932-26-004157 · form4.xml · nonDerivative · entry 2 Wider Todd · CIK 0001642715 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 672,247 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.10 to $6.25, inclusive. The reporting person undertakes to provide the Company, any stockholder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| June 29, 2026 Filed Jul 2, 2026 01:45 UTC | ASP Isotopes Inc. ASPI · Entity 5371 | SaleCommon Stock | 50,000 | $6.25 | $312,500.00 |
DisclosureSEC source: 0001477932-26-004157 · form4.xml · nonDerivative · entry 1 Wider Todd · CIK 0001642715 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 722,247 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.21 to $6.31, inclusive. The reporting person undertakes to provide ASP Isotopes Inc. (the "Company"), any stockholder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| December 18, 2025 Filed Dec 23, 2025 02:03 UTC | ASP Isotopes Inc. ASPI · Entity 5371 | GrantCommon Stock | 36,548 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001477932-25-009171 · form4.xml · nonDerivative · entry 1 Wider Todd · CIK 0001642715 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 772,247 F1 · price: Annual award of shares of restricted stock in connection with the reporting person's service as an independent director of ASP Isotopes Inc. Read SEC document |
| November 12, 2025 Filed Nov 15, 2025 02:34 UTC | ASP Isotopes Inc. ASPI · Entity 5371 | GrantCommon Stock | 25,469 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001477932-25-008354 · form4.xml · nonDerivative · entry 1 Wider Todd · CIK 0001642715 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 735,699 F1 · price: Award of shares of restricted stock in connection with the reporting person's service as an independent director of ASP Isotopes Inc. on the QLE Structuring and Strategic Transactions Committee. Read SEC document |
| September 15, 2025 Filed Oct 4, 2025 00:25 UTC | ASP Isotopes Inc. ASPI · Entity 5371 | SaleCommon Stock | 74,108 | $8.76 | $648,822.95 |
DisclosureSEC source: 0001477932-25-007349 · form4.xml · nonDerivative · entry 3 Wider Todd · CIK 0001642715 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 710,230 F2 · kind: The sale of shares reported in this Form 4 includes an amount for the purpose of satisfying the reporting person's income tax liabilities resulting from the vesting of a previously granted restricted stock award and the exercise of a stock option issued pursuant to an issuer equity incentive plan. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.37 to $9.40, inclusive. The reporting person undertakes to provide ASP Isotopes Inc. (the "Company"), any stockholder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in Footnote 3. Read SEC document |
| September 14, 2025 Filed Oct 4, 2025 00:25 UTC | ASP Isotopes Inc. ASPI · Entity 5371 | Exercise / conversionStock Option (right to buy) · Derivative | 96,000 | $0.00 Strike: $2.00 | $0.00 |
DisclosureSEC source: 0001477932-25-007349 · form4.xml · derivative · entry 4 Wider Todd · CIK 0001642715 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 96,000 shares Expires 2032-04-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: These options vested in a single installment 12 months after the grant date. The option was granted on April 4, 2022. Read SEC document |
| September 14, 2025 Filed Oct 4, 2025 00:25 UTC | ASP Isotopes Inc. ASPI · Entity 5371 | Tax withholdingCommon Stock | 21,892 | $8.77 | $191,992.84 |
DisclosureSEC source: 0001477932-25-007349 · form4.xml · nonDerivative · entry 2 Wider Todd · CIK 0001642715 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 784,338 F1 · kind: Represents shares withheld by the Company in connection with net share settlement to satisfy the exercise price associated with the reporting person's exercise of a stock option. Read SEC document |
| September 14, 2025 Filed Oct 4, 2025 00:25 UTC | ASP Isotopes Inc. ASPI · Entity 5371 | Exercise / conversionCommon Stock | 96,000 | $2.00 | $192,000.00 |
DisclosureSEC source: 0001477932-25-007349 · form4.xml · nonDerivative · entry 1 Wider Todd · CIK 0001642715 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 806,230 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 20, 2024 Filed Nov 22, 2024 00:34 UTC | ASP Isotopes Inc. ASPI · Entity 5371 | GrantCommon Stock | 42,522 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001477932-24-007551 · form4.xml · nonDerivative · entry 1 Wider Todd · CIK 0001642715 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 710,230 F1 · date: Annual award of common stock for service as an independent director of ASP Isotopes Inc. F1 · price: Annual award of common stock for service as an independent director of ASP Isotopes Inc. Read SEC document |
| August 13, 2024 Filed Aug 15, 2024 00:02 UTC | ASP Isotopes Inc. ASPI · Entity 5371 | GrantCommon Stock | 95,238 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001477932-24-004881 · form4.xml · nonDerivative · entry 2 Wider Todd · CIK 0001642715 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 667,708 F1 · date: This award of common stock was issued in lieu of quarterly cash fees payable to the reporting person for service as an independent director of ASP Isotopes Inc. F2 · price: Annual award of common stock for service as an independent director of ASP Isotopes Inc. Read SEC document |
| August 13, 2024 Filed Aug 15, 2024 00:02 UTC | ASP Isotopes Inc. ASPI · Entity 5371 | GrantCommon Stock | 77,626 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001477932-24-004881 · form4.xml · nonDerivative · entry 1 Wider Todd · CIK 0001642715 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 572,470 F1 · date: This award of common stock was issued in lieu of quarterly cash fees payable to the reporting person for service as an independent director of ASP Isotopes Inc. F1 · price: This award of common stock was issued in lieu of quarterly cash fees payable to the reporting person for service as an independent director of ASP Isotopes Inc. Read SEC document |
| July 31, 2024 Filed Aug 1, 2024 01:43 UTC | ARYA Sciences Acquisition Corp IV ARYD · Entity 88618 | Disposition to issuerClass B ordinary shares · Derivative | 30,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-24-035170 · form4.xml · derivative · entry 1 Wider Todd · CIK 0001642715 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A ordinary shares · 30,000 shares Expires not disclosed F1 · derivative.exercise_price: In connection with the Business Combination Agreement, dated February 13, 2024, by and among the Issuer, Adagio Medical Holdings, Inc. (f/k/a Aja HoldCo, Inc.) ("HoldCo"), Aja Merger Sub 1 ("Merger Sub 1"), Aja Merger Sub 2, Inc. ("Merger Sub 2") and Adagio Medical, Inc. ("Adagio") (the transactions contemplated thereby, the "Business Combination"), Merger Sub merged with and into the Issuer and Merger Sub 2 merged with and into Adagio, with each of the Issuer and Adagio becoming a wholly owned subsidiary of HoldCo, and the Reporting Person's ordinary shares of the Issuer were automatically converted into shares of common stock of HoldCo, par value $0.0001 per share, on a one-for-one basis. F1 · kind: In connection with the Business Combination Agreement, dated February 13, 2024, by and among the Issuer, Adagio Medical Holdings, Inc. (f/k/a Aja HoldCo, Inc.) ("HoldCo"), Aja Merger Sub 1 ("Merger Sub 1"), Aja Merger Sub 2, Inc. ("Merger Sub 2") and Adagio Medical, Inc. ("Adagio") (the transactions contemplated thereby, the "Business Combination"), Merger Sub merged with and into the Issuer and Merger Sub 2 merged with and into Adagio, with each of the Issuer and Adagio becoming a wholly owned subsidiary of HoldCo, and the Reporting Person's ordinary shares of the Issuer were automatically converted into shares of common stock of HoldCo, par value $0.0001 per share, on a one-for-one basis. F1 · price: In connection with the Business Combination Agreement, dated February 13, 2024, by and among the Issuer, Adagio Medical Holdings, Inc. (f/k/a Aja HoldCo, Inc.) ("HoldCo"), Aja Merger Sub 1 ("Merger Sub 1"), Aja Merger Sub 2, Inc. ("Merger Sub 2") and Adagio Medical, Inc. ("Adagio") (the transactions contemplated thereby, the "Business Combination"), Merger Sub merged with and into the Issuer and Merger Sub 2 merged with and into Adagio, with each of the Issuer and Adagio becoming a wholly owned subsidiary of HoldCo, and the Reporting Person's ordinary shares of the Issuer were automatically converted into shares of common stock of HoldCo, par value $0.0001 per share, on a one-for-one basis. F1 · derivative.exercise_date: In connection with the Business Combination Agreement, dated February 13, 2024, by and among the Issuer, Adagio Medical Holdings, Inc. (f/k/a Aja HoldCo, Inc.) ("HoldCo"), Aja Merger Sub 1 ("Merger Sub 1"), Aja Merger Sub 2, Inc. ("Merger Sub 2") and Adagio Medical, Inc. ("Adagio") (the transactions contemplated thereby, the "Business Combination"), Merger Sub merged with and into the Issuer and Merger Sub 2 merged with and into Adagio, with each of the Issuer and Adagio becoming a wholly owned subsidiary of HoldCo, and the Reporting Person's ordinary shares of the Issuer were automatically converted into shares of common stock of HoldCo, par value $0.0001 per share, on a one-for-one basis. F1 · derivative.expiration_date: In connection with the Business Combination Agreement, dated February 13, 2024, by and among the Issuer, Adagio Medical Holdings, Inc. (f/k/a Aja HoldCo, Inc.) ("HoldCo"), Aja Merger Sub 1 ("Merger Sub 1"), Aja Merger Sub 2, Inc. ("Merger Sub 2") and Adagio Medical, Inc. ("Adagio") (the transactions contemplated thereby, the "Business Combination"), Merger Sub merged with and into the Issuer and Merger Sub 2 merged with and into Adagio, with each of the Issuer and Adagio becoming a wholly owned subsidiary of HoldCo, and the Reporting Person's ordinary shares of the Issuer were automatically converted into shares of common stock of HoldCo, par value $0.0001 per share, on a one-for-one basis. Read SEC document |
| October 26, 2023 Filed Oct 31, 2023 01:51 UTC | ASP Isotopes Inc. ASPI · Entity 5371 | PurchaseCommon Stock | 94,844 | $0.96 | $91,050.24 |
DisclosureSEC source: 0001477932-23-007983 · form4.xml · nonDerivative · entry 1 Wider Todd · CIK 0001642715 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 494,844 F1 · deemedExecutionDate: Shares of the Issuer's Common Stock were purchased in the Issuer's private placement of Common pursuant to a Securities Purchase Agreement, dated October 9, 2023, by and among the Issuer and the other purchasers named therein. The shares of Common Stock acquired were purchased at a price per share of $0.96 per share of Common Stock (the consolidated closing bid price per share immediately preceding the signing of the binding agreement to issue the securities). Read SEC document |
| November 15, 2022 Filed Nov 16, 2022 17:50 UTC | ASP Isotopes Inc. ASPI · Entity 5371 | GrantCommon Stock | 200,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-22-073100 · ownership.xml · nonDerivative · entry 1 Wider Todd · CIK 0001642715 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 400,000 F1 · deemedExecutionDate: This special one-time equity award of 200,000 restricted shares was contingent upon the completion of our IPO. Mr. Wider will receive 100,000 restricted shares of our common stock on November 15, 2023 and 100,000 restricted shares of our common stock on November 15, 2024. Read SEC document |
| September 26, 2022 Filed Sep 28, 2022 20:36 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | GrantCommon Stock | 13,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-22-027047 · ownership.xml · nonDerivative · entry 1 Wider Todd · CIK 0001642715 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,907 F1 · shares: All of the restricted stock will vest on September 26, 2023. F2 · balance_after: On July 1, 2022, the issuer effectuated a 1-for-25 reverse stock split. Read SEC document |
| October 07, 2021 Filed Oct 9, 2021 00:33 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | SaleCommon Stock | 25,000 | $0.97 | $24,150.00 |
DisclosureSEC source: 0001493152-21-025086 · ownership.xml · nonDerivative · entry 1 Wider Todd · CIK 0001642715 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.9624 to $0.9661, inclusive. The reporting person undertakes to provide to the Issuer, any security holder, or the Staff of the SEC, upon request, full information regarding the number of shares disposed at each separate price within the ranges set forth in this footnote. Read SEC document |
| May 25, 2021 Filed May 28, 2021 01:49 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | GrantStock Option (right to buy) · Derivative | 49,084 | $0.00 Strike: $1.49 | $0.00 |
DisclosureSEC source: 0001493152-21-013125 · ownership.xml · derivative · entry 2 Wider Todd · CIK 0001642715 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,084 Underlying: Common Stock · 49,084 shares Expires 2031-05-25 F2 · derivative.exercise_date: All of the stock options will vest on November 25, 2021. Read SEC document |
| May 25, 2021 Filed May 28, 2021 01:49 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | GrantCommon Stock | 38,590 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-21-013125 · ownership.xml · nonDerivative · entry 1 Wider Todd · CIK 0001642715 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,590 F1 · shares: All of the restricted stock will vest on November 25, 2021. Read SEC document |
| February 19, 2021 Filed Feb 23, 2021 21:05 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | SaleCommon Stock | 251,625 | $2.39 | $601,056.64 |
DisclosureSEC source: 0001493152-21-004592 · ownership.xml · nonDerivative · entry 1 Wider Todd · CIK 0001642715 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 F1 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $2.371 to $2.402, inclusive. The reporting person undertakes to provide to the Issuer, any security holder, or the Staff of the SEC, upon request, full information regarding the number of shares disposed at each separate price within the ranges set forth in this footnote. Read SEC document |
| February 18, 2021 Filed Feb 19, 2021 21:05 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,345 | $0.00 Strike: $1.28 | $0.00 |
DisclosureSEC source: 0001493152-21-004407 · ownership.xml · derivative · entry 18 Wider Todd · CIK 0001642715 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,345 shares Expires 2030-05-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 18, 2021 Filed Feb 19, 2021 21:05 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | SaleCommon Stock | 1,345 | $2.43 | $3,272.79 |
DisclosureSEC source: 0001493152-21-004407 · ownership.xml · nonDerivative · entry 10 Wider Todd · CIK 0001642715 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 276,625 F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $2.43 to $2.45, inclusive. The reporting person undertakes to provide to the Issuer, any security holder, or the Staff of the SEC, upon request, full information regarding the number of shares disposed at each separate price within the ranges set forth in this footnote. Read SEC document |
| February 18, 2021 Filed Feb 19, 2021 21:05 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | Exercise / conversionCommon Stock | 1,345 | $1.28 | $1,721.60 |
DisclosureSEC source: 0001493152-21-004407 · ownership.xml · nonDerivative · entry 9 Wider Todd · CIK 0001642715 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 277,970 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 17, 2021 Filed Feb 19, 2021 21:05 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | Exercise / conversionStock Option (Right to Buy) · Derivative | 20,173 | $0.00 Strike: $1.28 | $0.00 |
DisclosureSEC source: 0001493152-21-004407 · ownership.xml · derivative · entry 17 Wider Todd · CIK 0001642715 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,345 Underlying: Common Stock · 20,173 shares Expires 2030-05-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 17, 2021 Filed Feb 19, 2021 21:05 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | Exercise / conversionStock Option (Right to Buy) · Derivative | 19,827 | $0.00 Strike: $1.28 | $0.00 |
DisclosureSEC source: 0001493152-21-004407 · ownership.xml · derivative · entry 16 Wider Todd · CIK 0001642715 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 19,827 shares Expires 2029-05-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 17, 2021 Filed Feb 19, 2021 21:05 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | Exercise / conversionStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $1.28 | $0.00 |
DisclosureSEC source: 0001493152-21-004407 · ownership.xml · derivative · entry 15 Wider Todd · CIK 0001642715 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 50,000 shares Expires 2028-03-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 17, 2021 Filed Feb 19, 2021 21:05 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | Exercise / conversionStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $1.28 | $0.00 |
DisclosureSEC source: 0001493152-21-004407 · ownership.xml · derivative · entry 14 Wider Todd · CIK 0001642715 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 30,000 shares Expires 2027-12-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 17, 2021 Filed Feb 19, 2021 21:05 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | Exercise / conversionStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $1.28 | $0.00 |
DisclosureSEC source: 0001493152-21-004407 · ownership.xml · derivative · entry 13 Wider Todd · CIK 0001642715 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 50,000 shares Expires 2026-12-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 17, 2021 Filed Feb 19, 2021 21:05 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | Exercise / conversionStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $1.28 | $0.00 |
DisclosureSEC source: 0001493152-21-004407 · ownership.xml · derivative · entry 12 Wider Todd · CIK 0001642715 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 50,000 shares Expires 2026-02-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 17, 2021 Filed Feb 19, 2021 21:05 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | Exercise / conversionStock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $1.28 | $0.00 |
DisclosureSEC source: 0001493152-21-004407 · ownership.xml · derivative · entry 11 Wider Todd · CIK 0001642715 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 100,000 shares Expires 2025-05-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 17, 2021 Filed Feb 19, 2021 21:05 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | SaleCommon Stock | 320,000 | $2.34 | $749,792.00 |
DisclosureSEC source: 0001493152-21-004407 · ownership.xml · nonDerivative · entry 8 Wider Todd · CIK 0001642715 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 276,625 F1 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $2.30 to $2.475, inclusive. The reporting person undertakes to provide to the Issuer, any security holder, or the Staff of the SEC, upon request, full information regarding the number of shares disposed at each separate price within the ranges set forth in this footnote. Read SEC document |
| February 17, 2021 Filed Feb 19, 2021 21:05 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | Exercise / conversionCommon Stock | 20,173 | $1.28 | $25,821.44 |
DisclosureSEC source: 0001493152-21-004407 · ownership.xml · nonDerivative · entry 7 Wider Todd · CIK 0001642715 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 596,625 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 17, 2021 Filed Feb 19, 2021 21:05 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | Exercise / conversionCommon Stock | 19,827 | $1.28 | $25,378.56 |
DisclosureSEC source: 0001493152-21-004407 · ownership.xml · nonDerivative · entry 6 Wider Todd · CIK 0001642715 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 576,452 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 17, 2021 Filed Feb 19, 2021 21:05 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | Exercise / conversionCommon Stock | 50,000 | $1.28 | $64,000.00 |
DisclosureSEC source: 0001493152-21-004407 · ownership.xml · nonDerivative · entry 5 Wider Todd · CIK 0001642715 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 566,625 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 17, 2021 Filed Feb 19, 2021 21:05 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | Exercise / conversionCommon Stock | 30,000 | $1.28 | $38,400.00 |
DisclosureSEC source: 0001493152-21-004407 · ownership.xml · nonDerivative · entry 4 Wider Todd · CIK 0001642715 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 506,625 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 17, 2021 Filed Feb 19, 2021 21:05 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | Exercise / conversionCommon Stock | 50,000 | $1.28 | $64,000.00 |
DisclosureSEC source: 0001493152-21-004407 · ownership.xml · nonDerivative · entry 3 Wider Todd · CIK 0001642715 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 476,625 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 17, 2021 Filed Feb 19, 2021 21:05 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | Exercise / conversionCommon Stock | 50,000 | $1.28 | $64,000.00 |
DisclosureSEC source: 0001493152-21-004407 · ownership.xml · nonDerivative · entry 2 Wider Todd · CIK 0001642715 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 426,625 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 17, 2021 Filed Feb 19, 2021 21:05 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | Exercise / conversionCommon Stock | 100,000 | $1.28 | $128,000.00 |
DisclosureSEC source: 0001493152-21-004407 · ownership.xml · nonDerivative · entry 1 Wider Todd · CIK 0001642715 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 376,625 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 00:09 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | SaleCommon Stock | 33,876 | $1.54 | $52,064.02 |
DisclosureSEC source: 0001493152-21-000249 · ownership.xml · nonDerivative · entry 2 Wider Todd · CIK 0001642715 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 276,625 F2 · kind: The sales reported in this Form 4 were to cover tax obligations associated with vested restricted stock awards and were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 19, 2020. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $1.50 to $1.575, inclusive. The reporting person undertakes to provide to the Issuer, any security holder, or the Staff of the SEC, upon request, full information regarding the number of shares disposed at each separate price within the ranges set forth in this footnote. Read SEC document |
| December 31, 2020 Filed Jan 6, 2021 00:09 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | Disposition to issuerCommon Stock | 609,755 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-21-000249 · ownership.xml · nonDerivative · entry 1 Wider Todd · CIK 0001642715 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 310,501 F1 · kind: Represents unvested shares of restricted common stock granted to the reporting person on October 8, 2020 in connection with the formation of a special committee of the Issuer's board of directors as reported on Form 8-K on October 6, 2020. These shares were scheduled to vest in monthly installments only while the special committee was operational and the reporting person was providing service to the special committee; the special committee was dissolved on December 31, 2020. The reporting person continues to serve on the Issuer's board of directors. Read SEC document |
| December 02, 2020 Filed Dec 2, 2020 21:26 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | SaleCommon Stock | 33,876 | $1.49 | $50,546.38 |
DisclosureSEC source: 0001493152-20-022828 · ownership.xml · nonDerivative · entry 1 Wider Todd · CIK 0001642715 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 920,256 F1 · kind: The sales reported in this Form 4 were to cover tax obligations associated with vested restricted stock awards and were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 19, 2020. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $1.46 to $1.565, inclusive. The reporting person undertakes to provide to the Issuer, any security holder, or the Staff of the SEC, upon request, full information regarding the number of shares disposed at each separate price within the ranges set forth in this footnote. Read SEC document |
| November 23, 2020 Filed Nov 24, 2020 23:46 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | SaleCommon Stock | 17,969 | $1.33 | $23,981.43 |
DisclosureSEC source: 0001493152-20-022466 · ownership.xml · nonDerivative · entry 1 Wider Todd · CIK 0001642715 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 954,132 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 19, 2020. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $1.32 to $1.37, inclusive. The reporting person undertakes to provide to the Issuer, any security holder, or the Staff of the SEC, upon request, full information regarding the number of shares disposed at each separate price within the ranges set forth in this footnote. Read SEC document |
| November 20, 2020 Filed Nov 20, 2020 23:00 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | Disposition to issuerStock Option (right to buy) · Derivative | 100,000 | Not disclosed Strike: $7.34 | Not disclosed |
DisclosureSEC source: 0001493152-20-022153 · ownership.xml · derivative · entry 14 Wider Todd · CIK 0001642715 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 100,000 shares Expires 2025-05-11 F2 · price: The options granted on May 20, 2020, May 21, 2019, March 29, 2018, December 14, 2017, December 13, 2016, February 11, 2016 and May 11, 2015 have each been modified to reflect a lower exercise price. F8 · derivative.exercise_date: The options vested 100% on November 11, 2015. Read SEC document |
| November 20, 2020 Filed Nov 20, 2020 23:00 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | GrantStock Option (right to buy) · Derivative | 100,000 | Not disclosed Strike: $1.28 | Not disclosed |
DisclosureSEC source: 0001493152-20-022153 · ownership.xml · derivative · entry 13 Wider Todd · CIK 0001642715 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2025-05-11 F2 · price: The options granted on May 20, 2020, May 21, 2019, March 29, 2018, December 14, 2017, December 13, 2016, February 11, 2016 and May 11, 2015 have each been modified to reflect a lower exercise price. F8 · derivative.exercise_date: The options vested 100% on November 11, 2015. Read SEC document |
| November 20, 2020 Filed Nov 20, 2020 23:00 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | Disposition to issuerStock Option (right to buy) · Derivative | 50,000 | Not disclosed Strike: $2.31 | Not disclosed |
DisclosureSEC source: 0001493152-20-022153 · ownership.xml · derivative · entry 12 Wider Todd · CIK 0001642715 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 50,000 shares Expires 2026-02-11 F2 · price: The options granted on May 20, 2020, May 21, 2019, March 29, 2018, December 14, 2017, December 13, 2016, February 11, 2016 and May 11, 2015 have each been modified to reflect a lower exercise price. F7 · derivative.exercise_date: The options vested 100% on August 11, 2016. Read SEC document |
| November 20, 2020 Filed Nov 20, 2020 23:00 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | GrantStock Option (right to buy) · Derivative | 50,000 | Not disclosed Strike: $1.28 | Not disclosed |
DisclosureSEC source: 0001493152-20-022153 · ownership.xml · derivative · entry 11 Wider Todd · CIK 0001642715 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2026-02-11 F2 · price: The options granted on May 20, 2020, May 21, 2019, March 29, 2018, December 14, 2017, December 13, 2016, February 11, 2016 and May 11, 2015 have each been modified to reflect a lower exercise price. F7 · derivative.exercise_date: The options vested 100% on August 11, 2016. Read SEC document |
| November 20, 2020 Filed Nov 20, 2020 23:00 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | Disposition to issuerStock Option (right to buy) · Derivative | 50,000 | Not disclosed Strike: $4.45 | Not disclosed |
DisclosureSEC source: 0001493152-20-022153 · ownership.xml · derivative · entry 10 Wider Todd · CIK 0001642715 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 50,000 shares Expires 2026-12-13 F2 · price: The options granted on May 20, 2020, May 21, 2019, March 29, 2018, December 14, 2017, December 13, 2016, February 11, 2016 and May 11, 2015 have each been modified to reflect a lower exercise price. F6 · derivative.exercise_date: The options vested 100% on June 13, 2017. Read SEC document |
| November 20, 2020 Filed Nov 20, 2020 23:00 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | GrantStock Option (right to buy) · Derivative | 50,000 | Not disclosed Strike: $1.28 | Not disclosed |
DisclosureSEC source: 0001493152-20-022153 · ownership.xml · derivative · entry 9 Wider Todd · CIK 0001642715 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2026-12-13 F2 · price: The options granted on May 20, 2020, May 21, 2019, March 29, 2018, December 14, 2017, December 13, 2016, February 11, 2016 and May 11, 2015 have each been modified to reflect a lower exercise price. F6 · derivative.exercise_date: The options vested 100% on June 13, 2017. Read SEC document |
| November 20, 2020 Filed Nov 20, 2020 23:00 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | Disposition to issuerStock Option (right to buy) · Derivative | 30,000 | Not disclosed Strike: $16.00 | Not disclosed |
DisclosureSEC source: 0001493152-20-022153 · ownership.xml · derivative · entry 8 Wider Todd · CIK 0001642715 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 30,000 shares Expires 2027-12-14 F2 · price: The options granted on May 20, 2020, May 21, 2019, March 29, 2018, December 14, 2017, December 13, 2016, February 11, 2016 and May 11, 2015 have each been modified to reflect a lower exercise price. F5 · derivative.exercise_date: The options vested 100% on June 14, 2018. Read SEC document |
| November 20, 2020 Filed Nov 20, 2020 23:00 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | GrantStock Option (right to buy) · Derivative | 30,000 | Not disclosed Strike: $1.28 | Not disclosed |
DisclosureSEC source: 0001493152-20-022153 · ownership.xml · derivative · entry 7 Wider Todd · CIK 0001642715 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2027-12-14 F2 · price: The options granted on May 20, 2020, May 21, 2019, March 29, 2018, December 14, 2017, December 13, 2016, February 11, 2016 and May 11, 2015 have each been modified to reflect a lower exercise price. F5 · derivative.exercise_date: The options vested 100% on June 14, 2018. Read SEC document |
| November 20, 2020 Filed Nov 20, 2020 23:00 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | Disposition to issuerStock Option (right to buy) · Derivative | 50,000 | Not disclosed Strike: $13.65 | Not disclosed |
DisclosureSEC source: 0001493152-20-022153 · ownership.xml · derivative · entry 6 Wider Todd · CIK 0001642715 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 50,000 shares Expires 2028-03-29 F2 · price: The options granted on May 20, 2020, May 21, 2019, March 29, 2018, December 14, 2017, December 13, 2016, February 11, 2016 and May 11, 2015 have each been modified to reflect a lower exercise price. F4 · derivative.exercise_date: The options vested 100% on September 29, 2018. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.